Overview
Awakn Life Sciences is a biotech company researching and developing ketamine and MDMA-based treatments for addiction disorders including alcohol use disorder, with clinical operations at their own therapy clinics in the UK. Their AWAKN-002 ketamine-assisted therapy program has completed Phase 2 clinical data for alcohol addiction.
More in Psychedelics
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
🍄 Psychedelics
Location
Bristol, UK
Funding
Public · NEO Exchange
Website
www.awakn.lifeListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →